https://www.selleckchem.com/pr....oducts/etomoxir-na-s
s. Compensating strategies can contribute to establishing a diagnosis. Docetaxel (DOC) and abiraterone (ABI) in the upfront setting have separately improved clinical outcomes for metastatic hormone-sensitive prostate cancer (mHSPC), but there are no studies comparing drug efficacies or the influence of racial disparities. We performed a retrospective multicenter review from Winship Cancer Institute at Emory University and Georgia Cancer Center for Excellence at Grady Memorial Hospital (2014-202 for patients with mHSPC treated
Like
Comment
Share
